People

Dr. Jingjing Sun is working as a senior postdoctoral associate in Prof. Peter Dedon’s group at SMART. She received her PhD degree (2017) in medicinal chemistry from Peking University. She then carried out postdoctoral research with Prof. Shana Sturla (2019) at ETH Zurich. After that, she moved to Boston and worked in Prof. Peter Dedon’s lab at MIT (2020-2022).

Post-transcriptional chemical modifications of RNA – collectively known as the epitranscriptome –have been discovered to be crucial regulators of gene expression in all living organisms. Accordingly, corrupted RNA modification is widely linked to pathology and disease, thus giving rise to a significant opportunity to target epitranscriptomic machinery for drug discovery.

Before at MIT, she developed a high-throughput RNA modification analysis platform to interrogate the epitranscriptome in bacteria and cancer panel. It is anticipated that this platform is capable of serving as a powerful tool for further understanding the mechanism of epitranscriptome-related diseases, leading to discovery of novel therapeutics and diagnostics. Currently, she is applying the high throughput RNA modification analysis platform to epitranscriptome drug development.

‍